BIOM-20. PROGNOSTIC VALUE OF HEMATOLOGIC PARAMETERS FOR PREDICTING RECURRENCE AND SHORT-TERM OUTCOMES IN NEWLY-DIAGNOSED GLIOBLASTOMA PATIENTS

Abstract BACKGROUND Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary brain tumor in adults, with a dismal prognosis. Recent studies have explored the prognostic significance of various hematologic parameters in GBM. However, their predictive utility for disease recurrence and short-term outcomes remains underexplored. This study aimed to assess the prognostic value of hematologic markers at various time points following initial GBM treatment and to determine their potential in detecting disease progression. METHODS We retrospectively analyzed 150 adult patients newly diagnosed with GBM between 2013 and 2022. Peripheral blood hematologic parameters—including white blood cell (WBC) count, absolute neutrophil count (ANC), platelet count, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR)—were collected. Patients were divided into two groups based on whether radiographic disease progression was observed on MRI within six months postoperatively. Continuous variables were compared using independent t-tests, while categorical variables were assessed using chi-square tests. A two-sided p-value of <0.05 was considered statistically significant. RESULTS Of the 150 patients, 71 exhibited disease progression within six months. Preoperative monocyte count (p = 0.041) and MLR (p = 0.048) were significantly higher in the progression group. At the six-month follow-up, WBC (p = 0.001), ANC (p < 0.001), NLR (p = 0.011), and platelet count (p = 0.031) were significantly elevated in patients with progression. Additionally, non-gross total resection was significantly associated with early disease progression (p = 0.002). CONCLUSIONS To our knowledge, this is the first study to demonstrate the prognostic significance of peripheral hematologic parameters at the six-month postoperative mark—a key but underexplored time point in GBM follow-up. These findings suggest a novel, accessible, and cost-effective approach to risk stratification in GBM patients.